menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Challenges in sAML Subtypes: t-AML & AML-MRC

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Managing secondary acute myeloid leukemia (sAML) subtypes, therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC), can be challenging, but these key considerations can help.  

  • Sponsored by

  • Overview

    t-AML and AML-MRC account for approximately 30 percent of all AML cases.1-3 Several challenges in managing these sAML subtypes include patient identification, treatment choice, and achieving remission and long-term survival.1,4-6 Let’s hear from Dr. Jonathan Abbas, Director of the Acute Leukemia and Blood Cancer Program with Tennessee Oncology in Nashville, as he shares some key strategies and considerations for managing patients with t-AML and AML-MRC.

    1. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367-1376.
    2. Nagel G, Weber D, Fromm E, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993-2003.
    3. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84(10):937-945.
    4. Arber DA, Erba HP. Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). Am J Clin Pathol. 2020;154(6):731-741.
    5. Grandfedlt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641-3649.
    6. Cheung E, Perissinotti AJ, Bixby DL, et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol. 2019;98(3):541-559.

    © 2022 Jazz Pharmaceuticals, Inc. US-OHD-2100310 Rev0522

Schedule26 Jun 2022
Webpack App